|
|
Alpha Tau Medical Ltd (NASDAQ: DRTS) |
|
Price: $3.7000
$0.47 
14.551%
|
| Day's High:
| $3.7
| Week Perf:
| 16.72 %
|
| Day's Low: |
$ 3.23 |
30 Day Perf: |
20.52 % |
| Volume (M): |
205 |
52 Wk High: |
$ 3.89 |
| Volume (M$): |
$ 758 |
52 Wk Avg: |
$2.58 |
| Open: |
$3.23 |
52 Wk Low: |
$1.75 |
|
|
| Market Capitalization (Millions $) |
0 |
| Shares
Outstanding (Millions) |
0 |
| Employees |
62 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
29 |
| Cash Flow (TTM) (Millions $) |
6 |
| Capital Exp. (TTM) (Millions $) |
6 |
Alpha Tau Medical Ltd
Alpha Tau Medical Ltd is a medical technology company that specializes in cancer treatment using a breakthrough technology called Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy). This innovative therapy involves the use of alpha-emitng radioactive atoms to target and destroy cancer cells, while sparing healthy surrounding tissues. Alpha Tau Medical aims to provide a non-invasive and effective treatment option for various types of solid tumors, including those that are resistant to other therapies. The company is dedicated to improving the lives of cancer patients and making a positive impact in the field of oncology.
Company Address: Kiryat HaMada St. 5 Jerusalem 9777605
Company Phone Number: (3) 577-4115 Stock Exchange / Ticker: NASDAQ DRTS
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Clinical Study
Published Thu, Oct 10 2024 12:30 PM UTC
CSIMarket.com October 10, 2024 In an exciting development for oncology, Alpha Tau Medical Ltd. announced today that it has treated its first patient with recurrent lung cancer using Alpha DaRT, a groundbreaking alpha-radiation therapy. This milestone was reached at the Hadassah Medical Center in Jerusalem, marking a significant step forward in the quest to provide effec...
|
Clinical Study
:'
Alpha Tau Medical Ltd., a company specializing in breakthrough cancer treatments using Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), has released compelling data in 'Cancers Journal' from four international clinical trials targeting various hard-to-treat superficial cancers. The findings offer promising long-term safety and efficacy profiles, potentially positioning Alpha Tau as a leader in the oncological treatment space.
Background:'
The landscape of cancer treatment has been continually evolving with innovative approaches aimed at increasing the efficacy and safety of therapies. Superficial cancers, including those affecting the skin, head, and neck, as well as the oral cavity, are notoriously difficult to treat due to their accessibility and potential disfigurement caused by conventional treatments. Alpha Tau?s Alpha DaRT technology represents a novel method, leveraging the power of alpha radiation to selectively target malignant cells while sparing the surrounding healthy tissue.
Clinical Trials and Data Analysis:'
The recent publication in 'Cancers Journal' consolidates data from four international clinical trials which spanned different superficial cancer indications. These trials were designed to evaluate both the long-term safety and efficacy of Alpha DaRT across various patient cohorts.
'Patient Cohorts:' The pooled analysis incorporated patients with skin, head & neck, and oral cavity cancers, highlighting the technology's versatile application across these challenging areas.
'Treatment Procedures:' The Alpha DaRT treatment involved inserting radium-loaded wires into the tumor mass, where they emitted alpha particles that selectively destroy cancerous cells.
'Safety Profile:' Throughout the long-term follow-up, patients exhibited minimal adverse effects, affirming the treatment's favorable safety profile accustomed to the targeted nature of alpha radiation.
'Efficacy:' The findings underscored significant efficacy, with notable tumor shrinkage and, in some cases, complete regression observed across patient cohorts.
Impact on Alpha Tau:'
The release of these long-term safety and efficacy data is not just a milestone for patients and the medical community, but also a strategic victory for Alpha Tau. Here's how:
'Reputation as a Pioneer:' The publication solidifies Alpha Tau's reputation as a pioneering force in the cancer treatment arena, with its technology demonstrating tangible, positive patient outcomes.
'Investor Confidence:' Robust clinical data can significantly boost investor confidence, potentially leading to increased funding and valuation.
'Regulatory Approval Pathway:' The positive outcomes pave the way for smoother regulatory approvals, as long-term safety and efficacy are critical considerations for agencies like the FDA.
'Market Penetration:' With such compelling data, Alpha Tau is well-positioned to accelerate its market penetration strategy, making its technology accessible to a broader patient population worldwide.
Conclusion:'
Alpha Tau?s Alpha DaRT technology showcases a remarkable innovation in the treatment of superficial cancers with promising long-term safety and efficacy. This development heralds a new era in oncology, offering hope to patients with few existing options. For Alpha Tau, the positive clinical trial outcomes not only reinforce its cutting-edge approach but also pave the way for substantial advances in cancer treatment.
Published Tue, Jun 25 2024 12:30 PM UTC
Abstract: Alpha Tau Medical Ltd., a company specializing in breakthrough cancer treatments using Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), has released compelling data in Cancers Journal from four international clinical trials targeting various hard-to-treat superficial cancers. The findings offer promising long-term safety and efficacy profiles, potentially...
|
| Clinical Study
Published Mon, May 13 2024 12:30 PM UTC
In recent years, significant advancements have been made in the field of oncology, particularly in the treatment of liver metastases resulting from colorectal cancer. Among these breakthroughs is Alpha Tau Medical Ltd. s groundbreaking alpha-radiation cancer therapy, Alpha DaRT. This article highlights the recent announcement of the treatment s first successful application o...
|
| Alpha Tau Medical Ltd
The Medical Equipment & Supplies sector is currently in the spotlight as contributors begin to analyze the fourth quarter of 2023 earnings. One significant player in the industry is Alpha Tau Medical Ltd, a renowned developer of alpha radiation cancer therapy. While the company has recently revealed positive interim safety and feasibility data from a pancreatic cancer study, there are several concerns that cast a bearish shadow over their future prospects.
Financial Performance:
Alpha Tau Medical Ltd reported an operating surplus of $35.68 million for the October to December 31, 2023 financial reporting period, surpassing last year's result of $32.136 million. However, it is crucial to note that the company has not specified any revenue yet. This absence of revenue raises questions about their ability to generate sustainable income and casts doubt on the long-term viability of the company.
|
| Product Service News
Published Tue, Nov 28 2023 1:30 PM UTC
Introduction
Alpha Tau Medical, a leading global developer of alpha radiation cancer therapy, has recently announced highly promising interim results from their safety and feasibility trial for the Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) treatment in advanced pancreatic cancer patients. The interim data for this innovative therapy demonstrate success...
|
| Per Share |
Current |
| Earnings (TTM) |
-0.42 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
86.06 $ |
| Cash |
1224.31 $
|
| Book Value |
1217.61 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.42 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
86.06 $ |
| Cash |
1224.31 $
|
| Book Value |
1217.61 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
